Related Experiment Video
Updated: Aug 21, 2026

Protocol for Long Duration Whole Body Hyperthermia in Mice
Published on: August 25, 2012
Malignant hyperthermia: pathophysiology, clinical presentation, and treatment
1University of Maryland, School of Nursing, Baltimore, USA. mcca003@son.umaryland.edu
Abstract:
Malignant hyperthermia (MH) was first described as an inherited highly lethal disorder in 1960. There has since been significant progress in the clinical management, identification of MH susceptible (MHS) persons, and understanding of the underlying pathophysiology. When patients are known to be MHS prior to surgery, an MH episode can easily be avoided by the use of safe nontriggering anesthetic agents. Current MH mortality is <10%, but many experts believe this can be significantly reduced by improved MH preparedness. MH is triggered in humans by an MH triggering anesthetic agent, which causes the release of calcium from the sarcoplastic reticulum of the skeletal muscle cell at an uncontrolled rate resulting in a hypermetabolic state. Recent molecular genetic studies have shown that MH is related to an abnormal ryanodine receptor that controls the release of calcium from the sarcoplastic reticulum. This article reviews the current understanding of the pathophysiology, diagnosis, clinical presentation, and treatment of MH.
More Related Videos
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
06:43Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management
Published on: November 21, 2017
Related Concept Videos
Increased Body Temperature
Homeostatic Imbalances in Body Temperature
Types of Fever
Here are the different types of fever:
Hyperthyroidism II: Pathophysiology
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Decreased Body Temperature